Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Xinhua News Agency pointed out that the important meeting held on the 9th analyzed and studied the economic work in 2025, in which the expression of monetary policy attracted people's attention. After a lapse of more than 10 years, the change of monetary policy orientation to "moderately loose" once again reflects the supportive monetary policy stance and sends a positive signal, which will strongly boost the confidence of all parties and help China's economy recover.Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;
Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Yiming Food issued a suggestive announcement on the risk of stock trading. Since November 26, 2024, the company's stock has been trading daily for 11 consecutive times, with a cumulative turnover rate of 66.9%, which is a risk of a sharp decline in the short term. At the same time, several major shareholders reduced their holdings of shares not exceeding 1% of the total share capital. As of the close of December 10, 2024, the three partnership platforms reduced their holdings by 138,200 shares today.Recently, all localities are vigorously promoting mergers and acquisitions, first in Shenzhen and then in Shanghai, and it is estimated that Beijing will soon. The listed companies in the north and Shenzhen are all active, and the merger of Shanghai benchmark brokerage Haitong+Guotai Junan has landed! Other places will follow suit, but mergers and acquisitions are really difficult to grasp, and it is estimated that there are more local+state-owned assets.
China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
12-13